Business Context and Reporting Period
Company: India Globalization Capital, Inc. (Note: Request metadata referenced "IGC Pharma, Inc.", but the filing identifies the registrant as India Globalization Capital, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2009
Event: Entry into a Material Definitive Agreement (ATM Agency Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses the following capital raising parameters:
- Maximum Aggregate Gross Proceeds: Up to $4,000,000.
- Commission Rate: 3% of the gross sales price per share.
- Securities: Common stock, par value $0.0001 per share.
- Registration: Under a shelf registration statement (Form S-3, File No. 333-160993) effective September 10, 2009.
Material Changes
The Company entered into an "At-The-Market" (ATM) Agency Agreement with Enclave Capital LLC. This agreement authorizes the Company to offer and sell shares through Enclave as a sales agent via ordinary brokers' transactions, privately negotiated transactions, crosses, or block transactions on the NYSE Amex at market prices.
Guidance, Outlook, and Risks
Management Commentary: The Company anticipates that Enclave Capital LLC may provide various investment banking, financial advisory, and other services to the Company and its affiliates for which customary fees may be received.
Risks/Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard terms of the ATM agreement. The sale of shares is subject to market conditions and the discretion of the Company.
Investor Verification Checklist
- Verify the current share price and trading volume on the NYSE Amex to assess the potential dilution impact of a $4 million offering.
- Review the Prospectus Supplement dated October 13, 2009, for the "Plan of Distribution" details referenced in this filing.
- Confirm the Company's current cash position and immediate capital needs to understand the urgency of this offering.
- Check for any subsequent filings indicating the actual amount of shares sold under this agreement.